Gefitinib Completed Phase 2 Trials for Prostate Cancer Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00265070Trial of Iressa in Prostate Cancer Patients
NCT00242918Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat Prostate Cancer
NCT00241475Gefitinib in the Treatment of the First Relapse of Prostate Cancer Beyond Prostatectomy or Radiotherapy
NCT00025116ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy